A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People

NCT05046873 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL
DRUG: semaglutide 1.34 mg/mL (placebo)
DRUG: Semaglutide 1.34 mg/mL
DRUG: NNC0480-0389 A 10 mg/mL

Sponsor

Novo Nordisk A/S